Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Trisodium Citrate→

Trisodium Citrate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
68-04-2
Molecular formula
C6H5Na3O7
Molecular weight
258.07 g/mol
Drug class
Alkalinising agenturinary citrate source and calcium-complexing ligand
Mechanism of action
Citrate is metabolised to bicarbonate, increasing systemic and urinary alkalinity. In urine it complexes calcium and increases urinary citrate, reducing supersaturation of calcium salts and inhibiting stone crystallisation. Sodium or potassium counter-ions affect electrolyte load and patient selection, but do not create a different citrate pharmacological target.
Indications / reported uses
  • Prevention and treatment of recurrent calcium-containing kidney stones associated with hypocitraturia
  • Alkali replacement in selected patients with renal tubular acidosis and hypocitraturia
  • Urinary alkalinisation in selected uric-acid or cystine stone disorders, depending on the specific citrate formulation and local product information

Sources: US DailyMed — Potassium citrate extended-release tablets · NIDDK — Kidney stones prevention and treatment · EAU Guidelines — Urolithiasis

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Trisodium Citrate Environmental Risk Assessment (ERA) (the Trisodium Citrate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.